Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998-2012.
Italy
cancer survivors
population-based cancer registries
relative risk
second primary cancer
thyroid cancer
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
14
07
2021
received:
17
05
2021
accepted:
14
07
2021
pubmed:
18
9
2021
medline:
3
3
2022
entrez:
17
9
2021
Statut:
ppublish
Résumé
The number of patients living after a cancer diagnosis is increasing, especially after thyroid cancer (TC). This study aims at evaluating both the risk of a second primary cancer (SPC) in TC patients and the risk of TC as a SPC. We analyzed two population-based cohorts of individuals with TC or other neoplasms diagnosed between 1998 and 2012, in 28 Italian areas covered by population-based cancer registries. Standardized incidence ratios (SIRs) of SPC were stratified by sex, age, and time since first cancer. A total of 38,535 TC patients and 1,329,624 patients with other primary cancers were included. The overall SIR was 1.16 (95% CI: 1.12-1.21) for SPC in TC patients, though no increase was shown for people with follicular (1.06) and medullary (0.95) TC. SPC with significantly increased SIRs was bone/soft tissue (2.0), breast (1.2), prostate (1.4), kidney (2.2), and hemolymphopoietic (1.4) cancers. The overall SIR for TC as a SPC was 1.49 (95% CI: 1.42-1.55), similar for all TC subtypes, and it was significantly increased for people diagnosed with head and neck (2.1), colon-rectum (1.4), lung (1.8), melanoma (2.0), bone/soft tissue (2.8), breast (1.3), corpus uteri (1.4), prostate (1.5), kidney (3.2), central nervous system (2.3), and hemolymphopoietic (1.8) cancers. The increased risk of TC after many other neoplasms and of few SPC after TC questions the best way to follow-up cancer patients, avoiding overdiagnosis and overtreatment for TC and, possibly, for other malignancies.
Sections du résumé
BACKGROUND
The number of patients living after a cancer diagnosis is increasing, especially after thyroid cancer (TC). This study aims at evaluating both the risk of a second primary cancer (SPC) in TC patients and the risk of TC as a SPC.
METHODS
We analyzed two population-based cohorts of individuals with TC or other neoplasms diagnosed between 1998 and 2012, in 28 Italian areas covered by population-based cancer registries. Standardized incidence ratios (SIRs) of SPC were stratified by sex, age, and time since first cancer.
RESULTS
A total of 38,535 TC patients and 1,329,624 patients with other primary cancers were included. The overall SIR was 1.16 (95% CI: 1.12-1.21) for SPC in TC patients, though no increase was shown for people with follicular (1.06) and medullary (0.95) TC. SPC with significantly increased SIRs was bone/soft tissue (2.0), breast (1.2), prostate (1.4), kidney (2.2), and hemolymphopoietic (1.4) cancers. The overall SIR for TC as a SPC was 1.49 (95% CI: 1.42-1.55), similar for all TC subtypes, and it was significantly increased for people diagnosed with head and neck (2.1), colon-rectum (1.4), lung (1.8), melanoma (2.0), bone/soft tissue (2.8), breast (1.3), corpus uteri (1.4), prostate (1.5), kidney (3.2), central nervous system (2.3), and hemolymphopoietic (1.8) cancers.
CONCLUSIONS
The increased risk of TC after many other neoplasms and of few SPC after TC questions the best way to follow-up cancer patients, avoiding overdiagnosis and overtreatment for TC and, possibly, for other malignancies.
Identifiants
pubmed: 34533289
doi: 10.1002/cam4.4193
pmc: PMC8495271
doi:
Types de publication
Historical Article
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6855-6867Subventions
Organisme : Italian Association for Cancer Research (AIRC)
ID : 16921
Organisme : Italian Ministry of Health, Ricerca Corrente
ID : RCR-2020-23670066
Organisme : Alliance Against Cancer: Overdiagnosis, overtreatment, and outcome in cancer patients
ID : WP 7
Informations de copyright
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Thyroid. 2015 Dec;25(12):1330-8
pubmed: 26442580
Epidemiol Prev. 2013 Jul-Oct;37(4-5 Suppl 1):1-152
pubmed: 24259384
Thyroid. 2018 Dec;28(12):1662-1673
pubmed: 30370820
Nat Rev Clin Oncol. 2016 Sep;13(9):550-65
pubmed: 27071351
Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):643-649
pubmed: 30541751
Eur J Cancer. 2018 May;94:6-15
pubmed: 29502036
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1029-36
pubmed: 27371756
Breast Cancer Res Treat. 2015 Jul;152(1):173-181
pubmed: 26058757
Epidemiol Prev. 2017 Mar-Apr;41(2 Suppl 1):1-244
pubmed: 28629213
N Engl J Med. 2016 Aug 18;375(7):614-7
pubmed: 27532827
J Public Health (Oxf). 2018 Jun 1;40(2):e91-e98
pubmed: 28977647
BMC Cancer. 2011 Feb 23;11:83
pubmed: 21342533
Thyroid. 2017 Jun;27(6):793-801
pubmed: 28338430
Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):231-8
pubmed: 26908594
Cancer Epidemiol. 2020 Feb;64:101664
pubmed: 31884334
Ann Surg Oncol. 2013 Apr;20(4):1341-7
pubmed: 23263698
Nat Rev Endocrinol. 2018 Sep;14(9):538-551
pubmed: 30069030
Med J Aust. 2020 Mar;212(4):163-168
pubmed: 31858624
Lancet Diabetes Endocrinol. 2020 Jun;8(6):468-470
pubmed: 32445733
Epidemiol Health. 2015 Mar 07;37:e2015015
pubmed: 25773442
Br J Cancer. 2003 Nov 3;89(9):1638-44
pubmed: 14583762
Cancer. 2011 Oct 1;117(19):4439-46
pubmed: 21432843
J Thyroid Res. 2018 Jun 26;2018:8765369
pubmed: 30046434
Cancer Med. 2021 Oct;10(19):6855-6867
pubmed: 34533289
J Clin Oncol. 2018 Jun 20;36(18):1831-1839
pubmed: 29252123
Lancet Diabetes Endocrinol. 2021 Mar;9(3):144-152
pubmed: 33482107
BMC Cancer. 2020 Jan 21;20(1):51
pubmed: 31964352
World J Urol. 2021 Jan 25;:
pubmed: 33492425
JAMA. 2020 Dec 22;324(24):2521-2535
pubmed: 33351041
Thyroid. 2013 May;23(5):575-82
pubmed: 23237308
Cancer Sci. 2012 Jun;103(6):1111-20
pubmed: 22364479
J Clin Endocrinol Metab. 2006 May;91(5):1819-25
pubmed: 16478820
Tumori. 2019 Apr;105(2):121-137
pubmed: 30917768
Int J Epidemiol. 2020 Oct 1;49(5):1517-1525
pubmed: 32984907
CMAJ. 2012 Jan 10;184(1):E57-69
pubmed: 22125331
Ann Surg Oncol. 2012 Jun;19(6):1887-96
pubmed: 22227921
Thyroid. 2015 Jun;25(6):681-7
pubmed: 25851829
Int J Cancer. 2020 Nov 15;147(10):2838-2846
pubmed: 32449158
J Clin Oncol. 2016 Oct 20;34(30):3672-3679
pubmed: 27601555
Cancer. 2015 Jan 15;121(2):259-68
pubmed: 25223713
J Clin Endocrinol Metab. 2000 May;85(5):1758-64
pubmed: 10843148
BMC Cancer. 2018 Feb 9;18(1):169
pubmed: 29426306
Surgery. 2016 Jan;159(1):132-40
pubmed: 26435427